Ceribell to Report Second Quarter 2025 Financial Results on August 5, 2025
Ceribell (Nasdaq: CBLL), a medical technology company specializing in neurological diagnostics, has scheduled its Q2 2025 financial results release for August 5, 2025, after market close.
The company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results. Investors can join via phone using the provided dial-in numbers and access code 7468193, or access the webcast through Ceribell's investor relations website.
Ceribell (Nasdaq: CBLL), un'azienda tecnologica nel settore medico specializzata in diagnostica neurologica, ha programmato la pubblicazione dei risultati finanziari del secondo trimestre 2025 per il 5 agosto 2025, dopo la chiusura del mercato.
La società terrà una conference call alle 13:30 PT / 16:30 ET dello stesso giorno per discutere i risultati. Gli investitori potranno partecipare telefonicamente utilizzando i numeri di accesso forniti e il codice 7468193, oppure seguire la diretta streaming tramite il sito web delle relazioni con gli investitori di Ceribell.
Ceribell (Nasdaq: CBLL), una empresa de tecnología médica especializada en diagnósticos neurológicos, ha programado la publicación de sus resultados financieros del segundo trimestre de 2025 para el 5 de agosto de 2025, después del cierre del mercado.
La compañía realizará una conferencia telefónica a las 1:30 p.m. PT / 4:30 p.m. ET ese mismo día para discutir los resultados. Los inversores pueden unirse por teléfono utilizando los números de acceso proporcionados y el código 7468193, o acceder a la transmisión en vivo a través del sitio web de relaciones con inversionistas de Ceribell.
Ceribell (나스닥: CBLL)은 신경 진단 전문 의료기술 회사로, 2025년 2분기 재무실적을 2025년 8월 5일 장 마감 후에 발표할 예정입니다.
회사는 같은 날 오후 1시 30분 PT / 오후 4시 30분 ET에 실적 발표 컨퍼런스 콜을 진행합니다. 투자자들은 제공된 전화 접속 번호와 접속 코드 7468193를 통해 전화로 참여하거나, Ceribell 투자자 관계 웹사이트를 통해 웹캐스트에 접속할 수 있습니다.
Ceribell (Nasdaq : CBLL), une entreprise de technologie médicale spécialisée dans le diagnostic neurologique, a programmé la publication de ses résultats financiers du deuxième trimestre 2025 pour le 5 août 2025, après la clôture du marché.
L'entreprise tiendra une conférence téléphonique à 13h30 PT / 16h30 ET le même jour pour discuter des résultats. Les investisseurs pourront participer par téléphone en utilisant les numéros d'appel fournis et le code d'accès 7468193, ou accéder au webinaire via le site des relations investisseurs de Ceribell.
Ceribell (Nasdaq: CBLL), ein Medizintechnikunternehmen, das sich auf neurologische Diagnostik spezialisiert hat, hat die Veröffentlichung seiner Finanzergebnisse für das zweite Quartal 2025 für den 5. August 2025 nach Börsenschluss geplant.
Das Unternehmen wird am selben Tag um 13:30 Uhr PT / 16:30 Uhr ET eine Telefonkonferenz abhalten, um die Ergebnisse zu besprechen. Investoren können telefonisch über die bereitgestellten Einwahlnummern und den Zugangscode 7468193 teilnehmen oder den Webcast über die Investor-Relations-Website von Ceribell verfolgen.
- None.
- None.
SUNNYVALE, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the second quarter of 2025 after the close of trading on Tuesday, August 5, 2025. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on August 5, 2025.
Investors interested in listening to the conference call may do so by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers and providing access code 7468193. A live and archived webcast of the event will be available in the "Investor Relations" section of the Ceribell website at https://investors.ceribell.com/.
About CeriBell, Inc.
Ceribell is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. Ceribell has developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence (“AI”)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA 510(k) cleared for indicating suspected seizure activity and currently utilized in intensive care units and emergency rooms across the U.S. Ceribell is headquartered in Sunnyvale, California. For more information, please visit www.ceribell.com or follow the company on LinkedIn.
Investor Contact
Brian Johnston or Laine Morgan
Gilmartin Group
Investors@ceribell.com
Media Contact
Corrie Rose
Press@ceribell.com
FAQ
When will Ceribell (CBLL) release its Q2 2025 earnings?
What time is Ceribell's Q2 2025 earnings conference call?
How can investors access Ceribell's Q2 2025 earnings call?
What does Ceribell (CBLL) company do?
